Reflecting on a recent podcast in discussion with a life sciences industry investor, Aman Wasan, CEO of ArisGlobal, considers how pharma R&D organisations should broaden their advanced automation ambitions within everyday operations to ensure a financially sustainable future.
The sustainable success of life sciences R&D organisations depends on their ability to maintain or grow profit while minimising the impact of significant and converging market pressures.
These range from high interest rates and soaring costs, to increased global supply chain challenges and intensifying competition.
Check out the rest of the feature here
